Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia

Neurotoxicity Research
David A LewisHarvey M Morris


Impairments in cognitive control, such as those involved in working memory, are associated with dysfunction of the dorsolateral prefrontal cortex (DLPFC) in individuals with schizophrenia. This dysfunction appears to result, at least in part, from abnormalities in GABA-mediated neurotransmission. In this paper, we review recent findings indicating that the altered DLPFC circuitry in subjects with schizophrenia reflects changes in the expression of genes that encode selective presynaptic and postsynaptic components of GABA neurotransmission. Specifically, using a combination of methods, we found that subjects with schizophrenia exhibited expression deficits in GABA-related transcripts encoding presynaptic regulators of GABA neurotransmission, neuropeptide markers of specific subpopulations of GABA neurons, and certain subunits of the GABA(A) receptor. In particular, alterations in the expression of the neuropeptide somatostatin suggested that GABA neurotransmission is impaired in the Martinotti subset of GABA neurons that target the dendrites of pyramidal cells. In contrast, none of the GABA-related transcripts assessed to date were altered in the DLPFC of monkeys chronically exposed to antipsychotic medications, suggesting that...Continue Reading


Mar 20, 2010·Neurotoxicity Research·Trevor ArcherRichard M Kostrzewa
Jul 14, 2010·Psychological Medicine·G K Murray
Jan 26, 2011·Molecular Psychiatry·R R KrishnanR S E Keefe
Jul 27, 2012·Translational Psychiatry·S KimMaree J Webster
Sep 29, 2009·Schizophrenia Bulletin·Sanghyeon Kim, Maree J Webster
Nov 3, 2010·Schizophrenia Bulletin·Korrapati V SathyasaikumarRobert Schwarcz
Jul 16, 2009·The Journal of Pharmacology and Experimental Therapeutics·Christina L BodarkySteven J Siegel
May 19, 2009·Annals of General Psychiatry·Shaheen E Lakhan, Karen F Vieira
May 23, 2012·Neuroscience Research·Ignacio González-BurgosMartha Martínez-Degollado
Oct 19, 2011·Pharmacology, Biochemistry, and Behavior·Stephen D GinsbergJohn F Smiley
Jul 14, 2010·Progress in Neurobiology·Matthijs G Bossong, Raymond J M Niesink
Sep 15, 2009·Biological Psychiatry·Max A CastilloPaula G Ulery-Reynolds
Jul 15, 2009·Progress in Neurobiology·Jacques EpelbaumCécile Viollet
Jan 22, 2010·Journal of Neurochemistry·Emma Perez-CostasRosalinda C Roberts
Nov 28, 2009·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Ricardo Noboro IsayamaEdna Nanami Yamasaki
Aug 19, 2015·Biological Psychiatry·Monika P JadiTerrence J Sejnowski
Jun 8, 2011·Schizophrenia Research·Neal R Swerdlow
Mar 19, 2014·Journal of Neurogenetics·Charmaine Y PietersenTsung-Ung W Woo
Jul 5, 2011·Neurochemistry International·Tadahiro NumakawaKazuo Hashido
Oct 9, 2012·Cerebral Cortex·Marina FrantsevaZafiris Jeffrey Daskalakis
Jul 13, 2011·The International Journal of Neuropsychopharmacology·Pierangelo Cifelli, Anthony A Grace
Feb 26, 2010·The International Journal of Neuropsychopharmacology·Lena DanovichHenry Silver
May 26, 2017·CNS Spectrums·Nuwan C HettigeVincenzo De Luca
Jul 23, 2014·Molecular Psychiatry·M FöckingD R Cotter
Nov 26, 2009·Expert Review of Proteomics·Nicoletta Baloyianni, George Th Tsangaris
Sep 19, 2019·Journal of Neural Transmission·Stephen J KaarOliver D Howes
Nov 1, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tiziana ImbriglioMilena Cannella
Aug 11, 2019·Nature Communications·Marianne L SeneyColleen A McClung


Jun 1, 1979·Brain : a Journal of Neurology·E D BirdL L Iversen
Jun 15, 1992·The Journal of Comparative Neurology·S M WilliamsC Leranth
Jan 31, 1992·Science·A Baddeley
Jan 1, 1990·Experimental Neurology·S A Bayer, J Altman
Dec 15, 1989·Neuroscience Letters·M D SimpsonW J Skan
Jun 3, 1995·Lancet·R C Gur, R E Gur
Feb 1, 1994·Archives of General Psychiatry·A J SaykinR C Gur
Mar 1, 1996·The American Journal of Psychiatry·M F Green
May 1, 1996·Schizophrenia Research·S F Taylor
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·H AsadaK Obata
Jul 1, 1997·The American Journal of Psychiatry·T U WooD Lewis
Sep 1, 1997·Cerebral Cortex·Y Kawaguchi, Y Kubota
Sep 12, 1998·The American Journal of Psychiatry·C S CarterJ D Cohen
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M M HuntsmanE G Jones
Mar 12, 1999·Science·E E Smith, J Jonides
Apr 9, 1999·Nature Neuroscience·A ReyesB Sakmann
Mar 20, 2001·Nature Reviews. Neuroscience·C J McBain, A Fisahn
Mar 20, 2001·Critical Reviews in Neurobiology·B Elvevåg, T E Goldberg
Apr 3, 2001·Annual Review of Neuroscience·E K Miller, J D Cohen
Jun 30, 2001·The American Journal of Psychiatry·W M PerlsteinJ D Cohen

Related Concepts

Presynaptic Terminals
Adrenal Cortex Diseases
Prefrontal Cortex
Synaptic Transmission
GABA-A Receptor
Gene Expression

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here